FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause Stop medicine if signs and symptoms of liver injury occur

https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due?utm_medium=email&utm_source=govdelivery Drug Safety Communication on Veozah (fezolinetant) FDA added a Boxed Warning, our most prominent warning, to highlight the known risk of rare but serious liver injury associated with use of menopause medicine Veozah (fezolinetant). In September, the FDA issued a drug safety communication warning that Veozah can cause rare but serious liver injury. If there are signs and symptoms suggesting liver injury, stopping the medicine could prevent worsening liver injury and potentially return liver function to normal. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216578s004lbl.pdf?utm_medium=email&utm_source=govdelivery